ADMA Biologics/ADMA

$6.20

0%
-
1D1W1MYTD1YMAX

About ADMA Biologics

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Ticker

ADMA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Adam Grossman

Employees

624

Headquarters

Ramsey, United States

ADMA Biologics Metrics

BasicAdvanced
$1.4B
Market cap
-
P/E ratio
-$0.13
EPS
0.45
Beta
-
Dividend rate
$1.4B
0.45238
$6.76
$3.06
2.54M
5.16
1.689
96.589
96.589
0.92%
-8.33%
-19.67%
-9.6%
5.421
10.099
10.672
366.562
67.59%
62.17%
82.88%

What the Analysts think about ADMA Biologics

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
35.16% upside
High $10.00
Low $7.50
$6.20
Current price
$8.38
Average price target

ADMA Biologics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-23.81% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$73.9M
9.97%
Net income
$-17.6M
-804%
Profit margin
-23.81%
-740.05%

ADMA Biologics Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 420%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.03
-$0.03
$0.01
-$0.08
-
Expected
-$0.04
-$0.03
-$0.01
$0.03
$0.06
Surprise
-29.41%
20%
-233.33%
-420%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for ADMA Biologics stock?

ADMA Biologics (ADMA) has a market cap of $1.44B as of April 21, 2024.

What is the P/E ratio for ADMA Biologics stock?

The price to earnings (P/E) ratio for ADMA Biologics (ADMA) stock is 0 as of April 21, 2024.

Does ADMA Biologics stock pay dividends?

No, ADMA Biologics (ADMA) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next ADMA Biologics dividend payment date?

ADMA Biologics (ADMA) stock does not pay dividends to its shareholders.

What is the beta indicator for ADMA Biologics?

ADMA Biologics (ADMA) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the ADMA Biologics stock price target?

The target price for ADMA Biologics (ADMA) stock is $8.38, which is 33.65% above the current price of $6.27. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell ADMA Biologics stock

Buy or sell ADMA Biologics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing